Expression of ERG in Lymphoblastic Lymphoma Patients: A Potential Diagnostic Pitfall

Wenyong Huang (wenyongh2009@yeah.net)
Nanchang University Second Affiliated Hospital

Wen Zhang
Nanchang University Second Affiliated Hospital

Lei Zeng
Nanchang University Second Affiliated Hospital

Yueer Zheng
Nanchang University Second Affiliated Hospital

Fangfang Hu
Nanchang University Second Affiliated Hospital

Fanrong Liu
Nanchang University Second Affiliated Hospital

Weisong Li
Gannan Medical University

Guangxiu Guo
Ganzhou People's Hospital

Lixiang Li
Nanchang University Second Affiliated Hospital

Short report

Keywords: ERG, Ewing's sarcoma, Lymphoblastic lymphomas, Diagnostic Pitfall

Posted Date: September 7th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-775822/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Expression of ERG in Lymphoblastic Lymphoma Patients: a Potential Diagnostic Pitfall

Wenyong Huang¹*, Wen Zhang¹, Lei Zeng¹, Yueer Zheng¹, Fangfang Hu¹, Fanrong Liu¹, Weisong Li², Guangxu Guo³, Lixiang Li¹

Abstract

Background: The Ets-related gene (ERG) is the member of ETS family of transcription factors, which commonly expressed in Ewing's sarcoma. Recently, we found that ERG can also express in lymphoblastic lymphoma. The aim of this article is to analyze the ERG expression in lymphoblastic lymphoma.

Methods: The patients of lymphoblastic lymphomas who had undergone fine needle aspiration or surgical operation from 2017 to 2021 in the second affiliated hospital of Nan-Chang university were collected and examined. Immunohistochemistry (IHC) was performed to evaluate the expression of ERG.

Results: In this study, 20 T-lymphoblastic lymphomas and 4 B-lymphoblastic lymphomas were investigated for the expression of ERG. Our findings showed that ERG was expressed in 8 of the 20 (40%) T-lymphoblastic lymphomas, and 3 of the 4 (75.0%) B-lymphoblastic lymphomas.

Conclusions: This report shows that ERG can express in lymphoblastic lymphomas, and highlights a potential diagnostic pitfall in the diagnosis of Ewing sarcoma, which urges pathologists to exercise caution in cases where ERG-positivity and illustrates the need for further immunohistochemical examination to avoid misdiagnosis.

Keywords: ERG, Ewing's sarcoma, Lymphoblastic lymphomas, Diagnostic Pitfall
Background

Lymphoblastic lymphomas are aggressive hematological malignancies consisting of small to medium-sized blast cells which are similar to other small round cell tumours. Most often, these malignancies manifest with extensive marrow and blood affectation, and sometimes as a mass lesion in the thymus or extranodal soft tissue. Actually, lymphoblastic lymphomas involving in the soft tissue may be confused with Ewing sarcoma, particularly when a limited panel of antibodies such as ERG, FLi-1 and CD99 are positive in both of them, which may lead to an erroneous diagnosis.

ERG is an ETS-family TF, which is a potent oncogene associated with both solid organ and hematologic malignancies. Chromosomal translocations that result in the expression of oncogenic ERG fusion proteins have been identified in leukemia, in Ewing sarcoma, and in 40%-80% of prostate carcinomas. Except the positive expression of ERG in Ewing sarcoma, recent research also showed that the Ewing sarcoma gene (EWS)–ERG fusion protein can not only transform mesenchymal progenitors into sarcomas, but also transform committed lymphocytes into T-cell leukemias in vivo. Besides, ERG is also temporally regulated during B lymphopoiesis, suggesting it may regulate B lymphoid development. Herein, we hypothesis that ERG may play a key role in the development of lymphoblastic lymphoma.

Methods

Tissue samples

This study included 20 T-lymphoblastic lymphoma and 4 B-lymphoblastic lymphoma patients, the pathological specimens come from the tissue archives of the department
of pathology, the second hospital of Nanchang university. The lymphoblastic lymphomas specimens were derived from patients who had undergone fine needle aspiration or surgical excision between 2017 and 2021. The histological sections were evaluated by four pathologists. Pathological diagnosis was determined by the use of histological features and immunohistochemical marker panels according to the newest World Health Organisation classification.

**Immunohistochemical staining**

Immunohistochemistry was performed on formalin fixed, paraffin-embedded tissue sections using the Dako Envision (Dako, Carpinteria, CA) automated system for the following antigens: ERG (ZA-0405, 1:100; ZSGB-Bio, Beijing, China), FLI-1 (ZA-0105, 1:50; ZSGB-Bio, Beijing, China), TdT (EP212, 1:100; ZSGB-Bio, Beijing, China), CD3 (EP41, 1:100; ZSGB-Bio, Beijing, China), Pax-5(Ep156, 1:100; ZSGB-Bio, Beijing, China) and CD99 (PCB1, 1:100; ZSGB-Bio, Beijing, China). All stainings were performed with appropriate positive and negative controls.

**Results**

The characteristics of patients with lymphoblastic lymphoma are presented in Table 1. All T-lymphoblastic lymphomas and B-lymphoblastic lymphomas had already been diagnosed using immunohistochemical staining. The age ranged from 8 to 55 years, and the median age is 31 years old. Cases 1 to 20 were T-lymphoblastic lymphomas, and Case 21, 22, 23 and 24 were B-lymphoblastic lymphomas.

The expression profiles of ERG in T-lymphoblastic lymphoma and B-lymphoblastic lymphoma are summarised in Table 1. Representative images of ERG immunohistochemical results in lymphoblastic lymphoma are shown in Fig. 1. ERG positive expression was observed in 8 (40%) of the 20 T-lymphoblastic lymphomas, and 3 (75.0%) of the all 4 B-lymphoblastic lymphomas. We confirmed positive ERG expression in the vascular endothelial cell of the tumor as a positive control.

Besides, the expression of FLI-1 was also observed in this study, and positive expression was found in 8 (66.6%) of the 12 T-lymphoblastic lymphomas, all 4...
(100.0%) of the B-lymphoblastic lymphomas showed strong positive expression (Fig. 2).

**Discussion**

Given to the overlapping histologic and immunohistochemical features, the differentiation of Ewing's sarcoma from lymphoblastic lymphoma are challenging, particularly in the small needle biopsy specimens. Immunohistochemical detection of ERG, FLI-1 and CD99 may be valuable in confirming the diagnosis of Ewing's sarcoma, while several reports have showed that ERG and FLI-1 are associated with the development of lymphoblastic lymphomas, and positive expression of lymphoblastic lymphoma had reported in literatures. In this study, we further evaluated the immunohistochemical staining with ERG in lymphoblastic lymphoma, and review literatures to avoid misdiagnosis.

Ewing sarcoma family tumors are characterized by the presence of non-random chromosomal translocations producing fusion genes that encode aberrant transcription factors. The t(11;22)(q24;q12) translocation is associated with 85% of tumors and leads to EWS-FLI-1 formation, whereas t(21;12)(22;12) and other less common translocations induced EWS-ERG fusion comprises the remaining 10% to 15% of cases. Hence, the expression of ERG and FLI-1 are widely used to the diagnosis of Ewing sarcoma and conformed to be the relatively sensitive markers of Ewing sarcoma.

However, ERG can also express in many other small round cell tumours except for the Ewing sarcoma. According to the recent reports, ERG is capable of promoting the development of leukemia and is crucial for its maintenance, which illustrates the possibility of the positive expression of ERG in lymphoblastic lymphoma. In this study, we found that ERG expressed in parts of lymphoblastic lymphoma. This reminds us that ERG is not a very specific marker for Ewing sarcoma, and we should exclude the possibility of lymphoblastic lymphoma when the small round cells positive express ERG. Interestingly, we found that ERG shows a more frequency of negative expression in T-lymphoblastic lymphomas of thymus than other sites in this
study. The reason for this phenomenon still unclear, one of the reasons we hypothesis is that the lymphoblastic lymphoma located in thymus is associated with DUX4 rearrangement which induces deregulation of ERG.\textsuperscript{13}

As ERG and FLI-1 are usually combining used to the diagnosis of Ewing sarcoma, here we also investigated the expression of FLI-1 in lymphoblastic lymphoma. In normal tissues, FLI-1 was found to be restricted to haematopoietic cells and endothelial cells. FLI-1 was mainly expressed in EWS with a specificity of over 90%, and later on it was added to CD99 as a useful marker in the histological diagnosis of EWS.\textsuperscript{14,15} However, further studies showed that FLI-1 was frequently seen in various tumour types, including vascular tumours, Merkel cell carcinoma (MCC) and desmoplastic small round cell tumour (DSRCT).\textsuperscript{16,17} In this study, we further investigated the expressional pattern of FLI-1 in lymphoblastic lymphoma and found that FLI-1 was positive expression in 8 (66.6\%) of the 12 T-lymphoblastic lymphomas and all 4 (100.0\%) of the B-lymphoblastic lymphomas. All these findings above indicates that ERG and FLI-1 are not enough in the diagnosis of Ewing sarcoma especially for the small needle specimens, and more extensive antibodies may be necessary to differentiate lymphoblastic lymphomas from Ewing sarcoma.

In conclusion, we performed ERG and FLI-1 in lymphoblastic lymphomas by immunophenotype analysis and showed that ERG and FLI-1 are positive in majority of lymphoblastic lymphomas, which urges pathologists to exercise caution in the diagnosis of Ewing sarcoma when ERG and FLI-1 are positivity, and illustrates the need for further immunohistochemical examination to avoid misdiagnosis.

**Abbreviations**

ERG: Ets-related gene; EWS: Ewing sarcoma gene; IHC: Immunohistochemistry; MCC: Merkel cell carcinoma; DSRCT: desmoplastic small round cell tumour

**Acknowledgements**

None.

**Author contributions**

Wenyong Huang and Wen Zhang performed the immunohistochemical expression
experiments, and prepared the figures and the manuscript. Lei Zeng, Yueer Zheng, Fangfang Hu, Fanrong Liu, Weisong Li and Guangxiu Guo contributed to the collection of the samples and corrected the data. Lixiang Li contributed with pathological diagnosis of the cases. Wenyong Huang and Lixiang Li designed the research. All authors have read and approved the final manuscript.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

The study protocol was approved by the ethics committee at the second affiliated hospital of Nanchang university, China.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Pathology, The Second Affiliated Hospital of Nanchang University, No.1, Minde Road, Donghu District, Nanchang 330000, China.

2. Department of Pathology, The First Affiliated Hospital of Gannan Medical University, No.23, Qingnian Road, Zhanggong District, Ganzhou 341000, China.

3. Department of Pathology, Ganzhou People's Hospital, No.17, Hongqi Avenue, Zhanggong District, Ganzhou 341000, China.

**References**

1. de Leval L, Bisig B, Thielen C, et al. Molecular classification of T-cell lymphomas. *Crit Rev Oncol Hematol*. 2009; 72: 125–143.

2. Loughran SJ, Kruse EA, Hacking DF, et al. The transcription factor ERG is essential for definitive hematopoiesis and the function of adult hematopoietic stem
cells. *Nat Immunol.* 2008; 9(7): 810-819.

3. Sorensen PH, Lessnick SL, Lopez-Terrada D, et al. A second Ewing’s sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. *Nat Genet.* 1994;6(2):146-151.

4. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. *Nature.* 2007; 448(7153):595-599.

5. Shimizu K, Ichikawa H, Tojo A, et al. An ets-related gene, ERG, is rearranged in human myeloid leukemia with t(16;21) chromosomal translocation. *Proc Natl Acad Sci U S A.* 1993;90(21): 10280-10284.

6. Rainis L, Toki T, Pimanda JE, et al. The protooncogene ERG in megakaryoblastic leukemias. *Cancer Res.* 2005; 65(17):7596-7602.

7. Taoudi S, Bee T, Hilton A, et al. ERG dependence distinguishes developmental control of hematopoietic stem cell maintenance from hematopoietic specification. *Genes Dev.* 2011; 25(3):251-262.

8. Codrington R, Pannell R, Forster A, et al. The Ews-ERG fusion protein can initiate neoplasia from lineage-committed haematopoietic cells. *PLoS Biol.* 2005; 3(8):e242.

9. Julie A I Thoms, Yehudit Birger, Sam Foster, et al. ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer. *Blood.* 2011; 117(26):7079-89.

10. A L Folpe, C E Hill, D M Parham, et al. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. *Am J Surg Pathol.* 2000; 24(12):1657-62.

11. Matthew Koo, Yasodha Natkunam. ERG Immunoreactivity in Blastic Hematolymphoid Neoplasms: Diagnostic Pitfall in the Workup of Undifferentiated Malignant Neoplasms. *Appl Immunohistochem Mol Morphol.* 2021; doi: 10.1097

12. Savita Sankar, Stephen L Lessnick. Promiscuous partnerships in Ewing's sarcoma. *Cancer Genet.* 2011; 204(7):351-65.
13. Jinghui Zhang, Kelly McCastlain, Hiroki Yoshihara, et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016; 48(12): 1481–1489.

14. Llombart-Bosch A, Navarro S. Immunohistochemical detection of EWS and FLi-1 proteins in Ewing sarcoma and primitive neuroectodermal tumors: comparative analysis with CD99 (MIC-2) expression. Appl Immunohistochem Mol Morphol. 2001; 9(3):255-60.

15. Folpe A L, Hill C E, Parham D M. et al. Immunohistochemical detection of FLi-1 protein expression. A study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am J Surg Pathol. 2000; 24(12):1657-62.

16. Folpe A L, Chand E M, Goldblum J R. et al. Expression of FLI-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol. 2001; 25(8):1061-6.

17. Llombart B, Monteagudo C, Lopez-Guerrero J A. et al. Clinicopathological and immunohistochemical analysis of 20 cases of merkel cell carcinoma in search of prognostic markers. Histopathology. 2005; 46(6):622-34.
| Case NO. | Age(y) | Sex | Tissue      | Diagnosis | ERG staining |
|---------|--------|-----|-------------|-----------|--------------|
| 1       | 29     | F   | LN          | T-LBL     | Positive     |
| 2       | 15     | M   | Mediastinum | T-LBL     | Negative     |
| 3       | 52     | M   | LN          | T-LBL     | Positive     |
| 4       | 28     | M   | Mediastinum | T-LBL     | Negative     |
| 5       | 20     | F   | LN          | T-LBL     | Negative     |
| 6       | 8      | M   | LN          | T-LBL     | Positive     |
| 7       | 12     | M   | Mediastinum | T-LBL     | Negative     |
| 8       | 21     | F   | Tonsil      | T-LBL     | Positive     |
| 9       | 32     | M   | Mediastinum | T-LBL     | Negative     |
| 10      | 42     | M   | Mediastinum | T-LBL     | Positive     |
| 11      | 46     | M   | LN          | T-LBL     | Positive     |
| 12      | 28     | F   | LN          | T-LBL     | Negative     |
| 13      | 22     | M   | Mediastinum | T-LBL     | Negative     |
| 14      | 25     | M   | LN          | T-LBL     | Positive     |
| 15      | 14     | M   | Mediastinum | T-LBL     | Negative     |
| 16      | 55     | F   | LN          | T-LBL     | Positive     |
| 17      | 54     | M   | LN          | T-LBL     | Negative     |
| 18      | 12     | M   | LN          | T-LBL     | Positive     |
| 19      | 43     | F   | LN          | T-LBL     | Positive     |
| 20      | 39     | M   | LN          | T-LBL     | Negative     |
| 21      | 44     | F   | Lumbar vertebral  | B-LBL | Positive  |
| 22      | 16     | F   | Pelvic      | B-LBL     | Positive     |
| 23      | 36     | F   | LN          | B-LBL     | Positive     |
| 24      | 50     | F   | Retroperitoneal | B-LBL | Negative  |
**Fig. 1** Morphological and immunohistochemical features in T-LBL. A) H&E stain of T-LBL. B) ERG, C) FLI-1, (D) CD99, (E) CD3 and (F) TdT positive expression in T-lymphoblastic lymphoma.
Fig. 2 A) ERG and B) FLI-1 positive expression in B-lymphoblastic lymphoma of lumbar vertebrae.